Abstract:Background: As the major microtubule organizing center in animal cells, the centrosome is implicated with human breast tumor in multiple ways, such as promotion of tumor cell immune evasion. Here, we aimed to detect the expression of centrosome-related genes (CRGs) in normal and malignant breast tissues, and construct a novel centrosome-related prognostic model to discover new biomarkers and screen drugs for breast cancer. Methods: We collected CRGs from the public databases and literature. The differentially expressed CRGs between normal and malignant breast tissues were identified by the DESeq2. Univariate Cox and LASSO regression analyses were conducted to screen candidate prognostic CRGs and develop a centrosome-related signature (CRS) to score breast cancer patients. We further manipulated and visualized data from TCGA, GEO, IMvigor210, TCIA and TIMER to explore the correlation between CRS and patient outcomes, clinical manifestations, mutational landscapes, tumor immune microenvironments, and responses to diverse therapies. Single cell analyses were performed to investigate the difference of immune cell landscape between high- and low-risk group patients. In addition, we constructed a nomogram to guide clinicians in precise treatment. Results: A total of 726 CRGs were collected from the public databases and literature. PSME2 , MAPK10 , EIF4EBP1 were screened as the prognostic genes in breast cancer. Next, we constructed a centrosome-related prognostic signature and validated its efficacy based on the genes for predicting the survival of breast cancer patients. The high-risk group patients had poor prognoses, the area under the ROC curve for 1-, 3-, and 5-year overall survival (OS) was 0.77, 0.67, and 0.65, respectively. The predictive capacity of CRS was validated by other datasets from GEO dataset. In addition, high-risk group patients exhibited elevated level of mutational landscapes and decreased level of immune infiltration, especially T and B lymphocytes. In terms of treatment responses, patients in the high-risk group were found to be resistant to immunotherapy but sensitive to chemotherapy. Moreover, we screened a series of candidate anticancer drugs with high sensitivity in the high-risk group. Conclusion: Our work exploited a centrosome-related prognostic signature and developed a predictive nomogram capable of accurately predicting breast cancer OS. The above discoveries provide deeper insights into the vital roles of the centrosome and contribute to the development of personalized treatment for breast cancer.

Significance of centromere protein genes and their associated immune and metabolic differences in the prediction of prognosis and treatment outcome in breast cancer

A Novel Coiled-Coil Domain Containing-Related Gene Signature for Predicting Prognosis and Treatment Effect of Breast Cancer.

Immune Infiltration Related CENPI Associates with the Malignant Features and Drug Resistance of Lung Adenocarcinoma.

A pan-cancer landscape of centromere proteins in tumorigenesis and anticancer drug sensitivity

Overexpression of Centromere Protein H is Significantly Associated with Breast Cancer Progression and Overall Patient Survival

Identification of a centrosome-related prognostic signature for breast cancer

Comprehensive Pan-Cancer Analysis Identifies Centromere-Associated Protein E As a Novel Prognostic and Immunological Biomarker in Human Tumors.

Integrative analysis of the expression and prognosis for CENPs in ovarian cancer

Expression and Significance of Centromere Protein B (CENP-B) in Breast Cancer

Overexpression of CENPF correlates with poor prognosis and tumor bone metastasis in breast cancer

Four centrosome-related genes to predict the prognosis and drug sensitivity of patients with colon cancer

Highly expressed CENPL is correlated with breast cancer cell proliferation and immune infiltration

Identification of Breast Cancer Immune-related Prognostic Characteristics in Tumor Microenvironment

The Prognostic Value and Mechanisms of Centromere Protein M in Patients with Lung Adenocarcinoma

The Role of CEP55 Expression in Tumor Immune Response and Prognosis of Patients with Non-small Cell Lung Cancer.

Prognostic Characteristics of Immune-Related Genes and the Related Regulatory Axis in Patients with Stage N+M0 Breast Cancer

High expression of centromere protein A and its molecular mechanism and clinical significance in prostate cancer: A study based on data mining and immunohistochemistry

[Centromere Protein U is Highly Expressed in Colorectal Cancer and Associated with a Poor Long-Term Prognosis].

Prognostic Value of Centromere Protein-A Expression in Patients with Epithelial Ovarian Cancer

Determination of Genetic and Epigenetic Modifications-Related Prognostic Biomarkers of Breast Cancer: Genome High-Throughput Data Analysis

Integrated Pan-Cancer Analysis of Centromere Protein F and Experimental Verification of Its Role and Clinical Significance in Cholangiocarcinoma.